A growing number of states are expanding restrictions on gifts to physicians from pharamceutical and medical device companies. In one recent example, Vermont has enacted new legislation that forbids almost all medical device manufacturer gifts to physcians. A brief summary of the new law is below. The following piece was authored by several of my colleagues at McGuireWoods. Please feel free to reach out to them with any questions you may have.
Vermont Expands Physician Gift Ban and Disclosure Policy to Apply to Device Manufacturers
The Vermont Legislature has enacted legislation (S.48) that prohibits drug and medical device manufacturers from offering gifts to health care providers and imposes broad financial relationship reporting requirements. The legislation expands and toughens the state’s existing physician gift ban and disclosure law. While the existing law only applies to pharmaceutical manufacturers, S.48 applies to both drug and device manufacturers. Under the new legislation, drug and device manufacturers must publicly disclose certain allowable expenditures made to doctors, nurses, medical staff, pharmacists, health plan administrators and facilities. The types of gifts S.48 prohibits include any type of payments, food, entertainment, travel, subscription, advance, service, and virtually anything of value provided to a health care provider for free.
The legislation exempts certain items from the general gift ban. Exempted items include samples, loans of medical devices for a short term trial period, the provision of medical devices for demonstrative or evaluative purposes, the provision of articles or journals serving a genuine educational function, scholarship, labels approved by the Federal Food and Drug Administration, and rebates and discounts. The legislation also allows manufacturers to make certain expenditures to health care providers. Allowable expenditures include, but are not limited to, payments for bona fide clinical trial and payments to the sponsors of a significant educational, medical, scientific, or policy-making conference or seminar.
Manufacturers providing allowable expenditures or exempted gifts to health care providers must make an annual disclosure of the payment’s value, nature, purpose, and recipient information. Manufacturers must also designate a person who will be responsible for their compliance with S.48 and disclose such individual’s name and address. Notably, the new legislation eliminates a previously existing exemption that restricted disclosure of trade secret information.
S.48 will take effect on July 1, 2009. A manufacturer violating S.48 may face a civil penalty up to $10,000 per violation. The Vermont Attorney General will be responsible for establishing reporting forms and enforcing this law.
Many legislatures around the nation are engaged in similar efforts to bring transparency to the drug and device manufacturer’s marking practices. A number of states, including Texas and Connecticut, have pending legislation that would ban certain gifts to health care providers and require disclosures of payments. Congress is also considering the Physician Payments Sunshine Act, which, if passed, may preempt certain state regulations and laws that require disclosure of information covered by the Federal legislation.
McGuireWoods LLP has formed a state compliance consortium to assist medical device manufacturers in complying with new state marketing compliance rules that have been passed in California, Massachusetts, and Nevada, the new Vermont law, and legislation pending in a number of additional states. The consortium will help medical device manufacturers keep abreast of these new laws and receive practical guidance to comply with the laws. This consortium will not be a lobbying effort but instead an effort to provide specific, practical guidance to help clients comply with the laws.
Please contact Kim Kannensohn at 312.750.8649 or Krist Werling at 312.750.8695 if you would like to participate or learn more about this consortium. For more information about our services, please visit our Life Sciences industry page.
| Kimberly J. Kannensohn 312.750.8649 kkannensohn@mcguirewoods.com |
| Kristian A. Werling 312.750.8695 kwerling@mcguirewoods.com |
| Ji Hye Kim 312.849.8222 jkim@mcguirewoods.com |
You Should Also Check Out This Post:
- Hospitals: Decreasing Costs While Increasing Quality and Innovation
- Radiation Oncology Consultation Payments Eliminated
- Lawsuits Between Nurses & Hospitals - McGuireWoods Teleconference
- The Radiation Boom - New York Times Article Critical of Radiation Therapy
- 8th Annual Business & Legal Issues in Dialysis & Nephrology Symposium
More Active Posts:
- Medicare Recovery Audit Contractors (RACs): What Providers Need to Know and How to Prepare (1)
- Medicare Recovery Audit Contractor (RAC) Update - Spring 2009 (1)
- Free Webinar: "Red Flag Rules for Physician Practices: Are You Ready for May 1st Enforcement?" (1)
- Radiation Oncology Consultation Payments Eliminated (1)










